Executives On The Move: New CEOs Named At Melinta Therapeutics And PIC Therapeutics
Swedish Orphan Biovitrum names R&D head while Regulus Therapeutics gets a new chief scientific officer and Zealand Pharma a new head of investor relations.
You may also be interested in...
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.
Plus promotions at Agios Pharmaceuticals, Bafna Pharmaceuticals, Miragen Therapeutics and Compass Therapeutics.